Journal of the American Academy of Dermatology
Volume 61, Issue 1 , Pages 104-111 , July 2009

Lichen planus–like eruptions: An emerging side effect of tumor necrosis factor-α antagonists

  • Adam Asarch, BA

      Affiliations

    • Department of Dermatology, Tufts Medical Center, Boston, Massachusetts
    • ,
  • Alice B. Gottlieb, MD, PhD

      Affiliations

    • Department of Dermatology, Tufts Medical Center, Boston, Massachusetts
    • ,
  • Jin Lee, MD, MBA

      Affiliations

    • Department of Dermatology, Tufts Medical Center, Boston, Massachusetts
    • ,
  • Katherine S. Masterpol, MD

      Affiliations

    • Department of Dermatology, Tufts Medical Center, Boston, Massachusetts
    • ,
  • Pamela L. Scheinman, MD

      Affiliations

    • Department of Dermatology, Tufts Medical Center, Boston, Massachusetts
    • ,
  • Miguel J. Stadecker, MD, PhD

      Affiliations

    • Department of Pathology, Tufts Medical Center, Boston, Massachusetts
    • ,
  • Elena M. Massarotti, MD

      Affiliations

    • Department of Rheumatology, Brigham and Women's Hospital, Boston, Massachusetts
    • ,
  • Michelle L. Bush, MD

      Affiliations

    • Department of Dermatology, Tufts Medical Center, Boston, Massachusetts
    • Corresponding Author InformationReprint requests: Michelle L. Bush, MD, Department of Dermatology, Tufts Medical Center, 800 Washington St, 114, Boston, MA 02111.

References 

  1. Wollina U, Hansel G, Koch A, Schonlebe J, Kostler E, Haroske G. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol. 2008;9:1–14
  2. de Gannes GC, Ghoreishi M, Pope J, Russell A, Bell D, Adams S, et al. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol. 2007;143:223–231
  3. Lee HH, Song IH, Friedrich M, Gauliard A, Detert J, Rowert J, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumor necrosis factor-alpha antagonists. Br J Dermatol. 2007;156:486–491
  4. Costa MF, Said NR, Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum. 2008;37:381–387
  5. Ramos-Casals M, Brito-Zeron P, Munoz S, Soria N, Galiana D, Bertolaccini L, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore). 2007;86:242–251
  6. Saint Marcoux B, De Bandt M. Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France. Joint Bone Spine. 2006;73:710–713
  7. Deng A, Harvey V, Sina B, Strobel D, Badros A, Junkins-Hopkins JM, et al. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors. Arch Dermatol. 2006;142:198–202
  8. Voulgari PV, Markatseli TE, Exarchou SA, Zioga A, Drosos AA. Granuloma annulare induced by anti-tumor necrosis factor therapy. Ann Rheum Dis. 2008;67:567–570
  9. Sun G, Wasko CA, Hsu S. Acneiform eruption following anti-TNF-a treatment: a report of 3 cases. J Drugs Dermatol. 2008;7:69–71
  10. Devos SA, Van Den Bossche N, De Vos M, Naeyaert JM. Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy. Dermatology. 2003;206:388–390
  11. Vergara G, Silvestre JF, Betlloch I, Vela P, Albares MP, Pascual JC. Cutaneous drug eruption to infliximab: report of 4 cases with an interface dermatitis pattern. Arch Dermatol. 2002;138:1258–1259
  12. Bovenschen JH, Kop EN, Van De Kerkhof PC, Seyger MM. Etanercept-induced lichenoid reaction pattern in psoriasis. J Dermatolog Treat. 2006;17:381–383
  13. Moss AC, Treister NS, Marsee DK, Cheifetz AS. Clinical challenges and images in GI: oral lichenoid reaction in a patient with Crohn's disease receiving infliximab. Gastroenterology. 2007;132:488, 829
  14. De Simone C, Caldarola G, D'Agostino M, Rotoli M, Capizzi R, Amerio P. Lichenoid reaction induced by adalimumab. J Eur Acad Dermatol Venereol. 2008;22:626–627
  15. Lebas D, Staumont-Salle D, Solau-Gervais E, Flipo RM, Delaporte E. Cutaneous manifestations during treatment with TNF-alpha blockers: 11 cases. [French] Ann Dermatol Venereol. 2007;134:337–342
  16. Battistella M, Rivet J, Bachelez H, Liote F. Lichen planus associated with etanercept. Br J Dermatol. 2007;158:188–190
  17. Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2005;7:R666–R676
  18. Seneschal J, Lepreux S, Bouyssou-Gauthier ML, Heliot-Hosten I, Economu A, Dehais J, et al. Psoriasiform drug eruptions under anti-TNF treatment of arthritis are not true psoriasis. Acta Derm Venereol. 2007;87:77–80
  19. Verea MM, Del Pozo J, Yebra-Pimentel MT, Porta A, Fonseca E. Psoriasiform eruption induced by infliximab. Ann Pharmacother. 2004;38:54–57
  20. Wenzel J, Scheler M, Proelss J, Bieber T, Tuting T. Type I interferon-associated cytotoxic inflammation in lichen planus. J Cutan Pathol. 2006;33:672–678
  21. Erdem MT, Gulec AI, Kiziltunc A, Yildirim A, Atasoy M. Increased serum levels of tumor necrosis factor alpha in lichen planus. Dermatology. 2003;207:367–370
  22. Akasu R, From L, Kahn HJ. Lymphocyte and macrophage subsets in active and inactive lesions of lichen planus. Am J Dermatopathol. 1993;15:217–223
  23. Carrozzo M, Uboldi de Capei M, Dametto E, Fasano ME, Arduino P, Broccoletti R, et al. Tumor necrosis factor-alpha and interferon-gamma polymorphisms contribute to susceptibility to oral lichen planus. J Invest Dermatol. 2004;122:87–94
  24. Pezelj-Ribaric S, Prso IB, Abram M, Glazar I, Brumini G, Simunovic-Soskic M. Salivary levels of tumor necrosis factor-alpha in oral lichen planus. Mediators Inflamm. 2004;13:131–133
  25. Rhodus NL, Cheng B, Bowles W, Myers S, Miller L, Ondrey F. Proinflammatory cytokine levels in saliva before and after treatment of (erosive) oral lichen planus with dexamethasone. Oral Dis. 2006;12:112–116
  26. Thongprasom K, Dhanuthai K, Sarideechaigul W, Chaiyarit P, Chaimusig M. Expression of TNF-alpha in oral lichen planus treated with fluocinolone acetonide 0.1%. J Oral Pathol Med. 2006;35:161–166
  27. Yarom N. Etanercept for the management of oral lichen planus. Am J Clin Dermatol. 2007;8:121
  28. Fiorentino DF. The yin and yang of TNF-{alpha} inhibition. Arch Dermatol. 2007;143:233–236
  29. Ritchlin C, Tausk F. A medical conundrum: onset of psoriasis in patients receiving anti-tumor necrosis factor agents. Ann Rheum Dis. 2006;65:1541–1544
  30. De Vries HJ, van Marle J, Teunissen MB, Picavet D, Zorgdrager F, Bos JD, et al. Lichen planus is associated with human herpesvirus type 7 replication and infiltration of plasmacytoid dendritic cells. Br J Dermatol. 2006;154:361–364
  31. Santoro A, Majorana A, Roversi L, Gentili F, Marrelli S, Vermi W, et al. Recruitment of dendritic cells in oral lichen planus. J Pathol. 2005;205:426–434
  32. Pinto JM, Marques MS, Correia TE. Lichen planus and leukocytoclastic vasculitis induced by interferon alpha-2b in a subject with HCV-related chronic active hepatitis. J Eur Acad Dermatol Venereol. 2003;17:193–195
  33. Saval AH, Martinez FC. Lichen planus induced by interferon-alpha-2b therapy in a patient with cutaneous malignant melanoma. Acta Derm Venereol. 1999;79:395
  34. Kutting B, Bohm M, Luger TA, Bonsmann G. Oropharyngeal lichen planus associated with interferon-alpha treatment for mycosis fungoides: a rare side-effect in the therapy of cutaneous lymphomas. Br J Dermatol. 1997;137:836–837

 Supported by a generous grant from Ms Joan Fabry. Tufts Medical Center has received educational/research grants from Centocor, Amgen, Wyeth, Immune Control, Celgene, Incyte, and Abbott.

 Disclosure: Almost all of Dr Gottlieb's income is paid to her employer. Dr Gottlieb has speakers' bureau memberships with Amgen Inc and Wyeth Pharmaceuticals. Dr Gottlieb has current consulting/advisory board agreements with Amgen Inc, Centocor Inc, Wyeth Pharmaceuticals, Celgene Corp, Bristol Myers Squibb Co, Beiersdorf Inc, Warner Chilcott, Abbott Laboratories, Roche, Sankyo, Medarex, Kemia, Celera, TEVA, Actelion, UCB, Novo Nordisk, Almirall, Immune Control, RxClinical, Dermipsor Ltd, Medacorp, DermiPsor, Can-Fite, Incyte, and Corgentech. Ms Fabry is a patient of Dr Gottlieb's and gave an unrestricted grant to support psoriasis research. Dr Massarotti receives consulting/honoraria from Bristol Myers Squibb, UCB, Genentech, Abbott, and PAI. Dr Bush has received research funding from Centocor. Mr Asarch, and Drs Lee, Masterpol, Scheinman, and Stadecker have no conflicts of interest to declare.

 Case 1 was presented at a meeting of the New England Dermatological Society at Tufts Medical Center, Boston, MA, on December 1, 2007.

PII: S0190-9622(08)01212-7

doi: 10.1016/j.jaad.2008.09.032

Journal of the American Academy of Dermatology
Volume 61, Issue 1 , Pages 104-111 , July 2009

Article Tools

* Image Usage & Resolution